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Abstract: Receptor tyrosine kinases (RTKs) are cell surface transmembrane proteins
responsible for intracellular signal transduction. They are expressed in several cell types
and, after activation by growth factor binding, trigger a series of intracellular pathways,
leading to a wide variety of cell responses (e.g., differentiation, proliferation, migration
and invasion, angiogenesis, survival). Over-expression and/or structural alteration of
RTKs family members are often associated to human cancers and tumor cells are known
to use RTK transduction pathways to achieve tumor growth, angiogenesis and
metastasis.  Therefore,  RTKs represent pivotal target in  approaches of cancer  therapy.  A
number of small molecules acting as RTK inhibitors have been synthesized by pharmaceutical companies and
are under clinical trials, are being analyzed in animal models or have been successfully marketed. Ligand-
dependent downregulation of RTKs is a critical step for modulating their activity and the adaptor Cbl has been
indicated as the key protein involved in negative regulation of RTKs, such as EGF and HGF receptors. These
data suggest novel potential pharmacological targets for the treatment of human malignancies associated to
oncogenic activation of RTKs.
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RECEPTOR TYROSINE KINASES (RTKS)
Growth factors are extracellular signals that regulate cell
proliferation and differentiation. The vast majority of them,
such as Platelet-Derived Growth Factor (PDGF), Epidermal
Growth Factor (EGF), Fibroblast Growth Factor (FGF),
Vascular Endothelial Growth Factor (VEGF), Hepatocyte
Growth Factor (HGF) and others, bind to receptors with
tyrosine kinase activity (RTKs), which have been often
involved in human cancers. RTKs consist of an extracellular
ligand binding domain, usually glycosylated, connected to
the cytoplasmic domain by a single transmembrane helix.
The intracellular domain contains a conserved protein
tyrosine kinase core and additional regulatory sequences that
undergo phosphorylation. The extracellular domain displays
different structural elements, such as one or more copies of
Immunoglobulin-like domains, fibronectin type III-like
repeats, EGF-like domains, cysteine-rich regions and other
features [1].
Based on their structural extracellular characteristics,
RTKs can be classified into approximately twenty families.
Some examples of receptors altered in human cancer are
listed here: family I, EGF receptor and its homologs, with
two cysteine-rich domains; family III, PDGF receptors, with
five Immunoglobulin-like domains; family IV, FGF
receptors, with three Immunoglobulin-like domains; family
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V, VEGF receptors with seven immunoglobulin domains;
family VI, the HGF receptor and its homologs, that have a
heterodimeric structure; family XIV, the Ret receptor with a
Cadherin repeat and a cysteine-rich region. RTKs belong to a
large family of proteins with a wide range of functions,
including proliferation, migration, differentiation,
morphogenesis and metabolism [1].
The main hallmark of this family is an intrinsic
enzymatic activity that catalyzes the transfer of the γ-
phosphate of ATP to tyrosine residues in protein substrates.
With the only exception of the insulin receptor family, all
known RTKs are monomers in the cell membrane. Ligand
binding in the extracellular domain induces receptor
dimerization and trans-phosphorylation of specific tyrosine
residues located in the cytoplasmic portion of the receptor
[2]. The currently accepted model for RTKs dimerization
proposes that active dimers exist even in the absence of
ligand binding, since auto/trans-phosphorylation of RTKs
can be obtained either by using inhibitors of protein tyrosine
phosphatases (PTPs) or by receptor over-expression. The
effect of ligand binding to the extracellular domain of the
receptor stabilizes the formation of active dimers and
consequently the activation of the kinase activity.
Ligand-induced dimerization is a process required during
RTKs activation, even if different ligands can use different
strategies to induce this active dimeric condition. Receptor
dimerization is further stabilized by additional receptor-
receptor interactions [3-4]. In the case of homodimeric
growth factors, as PDGF, the receptor becomes dimerised by
direct interaction with the ligand. In some cases, an
accessory protein is required to complete the ligand-mediated
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receptor dimerization. As an example, heparin or heparan
sulphate proteoglycans play an essential role in stabilizing
the FGF and HGF receptor dimers [5-6].
In recent years, structural studies by X-ray
crystallography have been essential to reveal the molecular
mechanisms by which RTKs become activated, following
dimerization and tyrosine auto-phosphorylation [7]. The
crystal structure of the insulin receptor tyrosine kinase in
both active and inactive conformation revealed a twofold
mechanism for activation. In the inactive state, the activation
loop (A-loop) of the kinase domain occupies the active site,
blocking the access to substrate and ATP. Once
phosphorylated in three tyrosine residues within the loop
(Y1158, Y1162, Y1163), it undergoes a major
conformational change moving the activation loop away
from the active site, resulting in free access for ATP and
protein substrates to the kinase active site [8-9]. In this
model, phosphorylated Y1163 is the key regulator in
stabilizing the conformation of the activation loop, whereas
pY1158 is completely exposed to solvent, suggesting
availability for interaction with downstream signaling
proteins. The importance of this alternative docking site is
elucidated in the case of APS-SH2B adapter family, that
selectively bind tyrosine residues in the activation loop of
RTKs, acting as negative regulator of receptor signaling
[10].
The crystal structure of Fibroblast Growth Factor
Receptor 1 (FGFR1K) revealed several differences from the
tyrosine kinase domain of insulin receptor. Residues in the
A-loop of FGFR1K appear to interfere with substrate peptide
binding, but not with ATP binding, providing a second and
perhaps more general auto-inhibitory mechanism for RTKs
[11].
Mechanisms of RTKs Signal Generation
As stated above, upon binding to their ligands, RTK
molecules dimerise and undergo autophosphorylation on
specific tyrosine residues, generally located in the non-
catalytic regions of the receptor molecule. In turn, these
phosphotyrosines and their adjacent sequences specifically
recruit downstream signaling molecules, generally through
SH2 (Src-Homology 2) or PTB (PhosphoTyrosine Binding)
domains, causing their subsequent phosphorylation. Many
of these proteins contain intrinsic enzymatic activities (Src
kinases, Shp2 PTP, PLC-γ, or Ras-GAP) and/or protein
modules that mediate interactions with other proteins,
phospholipids or nucleic acids. A number of protein
modules have been shown to be involved in cellular
signaling downstream of RTKs and of other cell surface
receptors, mediating either constitutive or ligand-dependent
associations [12].
Recruitment of proteins onto RTKs leads to their
activation by virtue of three mechanisms: a) recruitment to
the plasma membrane, i.e. to a subcellular compartment
where substrates are available; b) allosteric changes induced
by phosphotyrosine-directed protein-protein interactions; c)
direct phosphorylation on specific tyrosine residues.
Ultimately, the definition of the cellular response is
governed by coupling to diverse signaling molecules which
create a complex network of molecular interaction cascades.
Signals that stimulate different mitogen-activated protein
(MAP) kinases are of special importance in the control of
cell growth, differentiation and other responses, because they
provide a link to Transcription Factor(s) activation and
induction of gene expression [13].
RTK Signaling by Heterodimeric Aggregates
Recent insights have strongly enhanced the diversity of
possible cell response modulation parameters. These include
the realization of heterologous RTK interaction. The
formation of heterodimeric receptor complexes, which are
composed of closely related RTK members, can contribute
to enhance or modify signal generation. Heterodimer
formations have been observed for PDGF α and β receptors,
the EGF receptor family, the FGF receptor family, the
Neurotrophin receptor family, the HGF receptor family and
raise the possibility that heterodimer formation may be
involved in a wide range of cellular responses [2]. In such a
context, the different affinity of a ligand for distinct receptor
combinations might have a fundamental importance in
signal modulation.
RTK Activation by Ligand-Independent Mechanisms
The activation of RTKs can also occur in a ligand-
independent manner. Mutation in the extracellular as well as
in the kinase domain of a given RTK may result in its
constitutive activation. This may occur even in the ligand
absence, due to novel inter-molecular contacts that facilitate
receptor dimerization and activation. Alternatively,
mutations occurring in the kinase domain give rise to
activated receptor, by alteration of the activation loop, the
ATP binding site of the glycine loop or of the substrate
binding pocket. Constitutively activated receptors are
associated with a number of human diseases, Ret and Met
point mutations (see below) being particularly involved in
neoplastic syndromes [1].
Mechanism of Signal Attenuation and Termination
The activity of RTKs must be tightly regulated and
properly balanced in order to mediate their normal cellular
tasks and many physiological processes. Generations of
aberrant forms, over-expression and/or dysfunction of RTKs
are associated to several diseases, including cancer.
Different mechanisms have been developed for
attenuation and termination of RTKs signaling. These
include different strategies: a) expression of antagonistic
ligands, (EGF-like protein Argos in Drosophila that binds to
EGF receptor and, by competing with Spitz for the receptor
binding, inhibits EGFR activity [14]); b) inhibition of
tyrosine kinase activity of the receptor either by receptor
modification, such as serine phosphorylation (PKC-mediated
phosphorylation of EGFR strongly inhibits EGF binding to
the extracellular domain of the EGFR [15]), or by direct
binding to the tyrosine kinase domain through SH2 domains
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(SOCS family functions as a negative regulator for feedback
inhibition in response to cytokine stimulation [16]), as well
as by competitive inhibitors of ATP binding to tyrosine
kinase (see below); c) inhibition by PTPs (Protein-Tyrosine
Phosphatases), which plays a major role in RTK negative
regulation [17]; d) ligand-induced endocytosis of ligand-
receptor complexes, which leads to attenuation of receptor
signaling and could therefore be considered as a tumor-
suppressor pathway [18].
Given the relevance of activated RTKs in cancer, one
could expect that PTP genes would have been found as
tumor suppressor genes. However, this does not seem to be
the case in general, even if it has been reported that the
PTEN/MMAC gene (which is mutated in some sporadic
cancers and in the Cowden’s hamartoma cancer syndrome)
encodes a member of the dual–specificity protein
phosphatase family [19].
RTKs SELECTIVE ANTICANCER DRUGS: AN
UPDATE
This chapter is intended to give a review on the
development of selective tyrosine kinase inhibitors as anti-
cancer drugs. Other important approaches, such as antibodies
against the receptor and/or ligand, soluble forms of growth
factor receptors, ribozymes, antisense ribonucleotides,
phosphatase inhibitors or SH2/SH3-directed agents etc., will
not be discussed here.
Selected tyrosine kinase inhibitors, particularly attractive
for some physico-chemical and/or pharmacokinetic features,
will be summarized. These are recently approved and
marketed drugs for cancer treatment, agents currently under
clinical trials or molecules with significant potential to treat
clinical cancer. These agents will be presented according to
RTK subfamily that they inhibit.
Current cancer treatment relies on administration of
cytotoxic drugs that act on both tumor and normal cells.
Usually the therapy consists of the combination of two or
more agents, also in an effort to reinforce the anti-tumoral
efficacy and to delay and/or to avoid development of drug
resistance.
In the past twenty years an increasing number of studies
have been directed to the molecular mechanisms of
neoplastic transformation and tumor progression. In
particular, most of our knowledge on the mechanisms of cell
transformation is focused on the signaling pathways leading
to cell proliferation, migration and survival, evoked by
intracellular tyrosine kinase activity. Moreover, as stated
above, the molecular structure of the tyrosine kinase domain
has been elucidated by X-ray crystallography. This enabled
the search for more selective and less cytotoxic drugs, from
naturally derived to synthetic compounds, based on
molecular modeling of the tyrosine kinase domain of
individual membrane RTKs.
Growing evidences point to new discovered compounds
that have been developed and/or are under testing, as
clinically useful cancer chemotherapeutic agents, specific for
some of the several RTKs families. In the following section,
recent advances on this topic will be summarized.
Tyrosine Kinase Inhibitors of EGF Receptor Family
The EGF receptor was the first discovered member of the
wide HER/erbB family of membrane RTKs, including
HER2-neu/erbB2 and heregulin or neuregulin receptors
HER3/erbB3 and HER4/erbB4. A large number of solid
tumors (gastrointestinal tract, non-small cell lung, breast,
prostate, bladder and ovarian carcinomas, head and neck
cancers, glioblastoma) display overexpression or structural
alteration of EGF receptor family members, associated to
poor prognosis and, in some cases, to resistance to hormone
therapy, cytotoxic agents and radiotherapy [20-23]. The most
common EGF receptor mutant found in human cancer is
EGFRvIII [24]. It is a truncated receptor lacking domains I
and II of the extracellular portion and being incapable of
ligand binding: however, it shows a constitutively activated
tyrosine kinase domain that stimulates cell proliferation
independently of ligand interaction [21]. The main signaling
pathways of this family of receptors are Ras-MAPK, mainly
involved in cell proliferation and PI-3 kinase/Akt,
responsible for cell cycle progression and survival from
apoptosis [23, 25].
Due of the relevance of these RTKs to the development
of human cancer, pharmacological researches focused for
several years on inhibitors of the tyrosine kinase activity,
responsible for the receptor functions, to be developed as
potential anticancer drugs. Moreover, because of the multiple
ligands for a given receptor, targeting of the kinase is a
particularly advantageous approach to inhibit these receptors.
Most of these agents are low-molecular-weight molecules
that inhibit tyrosine trans-phosphorylation of the
intracellular moieties in homodimerised receptors, by
interfering with the kinase domain ATP binding site [26].
These agents were initially identified as naturally derived
molecules, the isoflavone genistein being the first
discovered. It is an ATP competitive inhibitor, but it acts at
high concentrations in vitro and it is not selective for the
EGF receptor. Moreover it also exerts actions independent of
tyrosine kinase inhibition, such as estrogen receptor binding
and modulation [27]. Selectivity of genistein has been
ameliorated by generation of a conjugate made of human
recombinant EGF fused to genistein. This showed good
tolerability in animals and enhanced anti-tumoral activity on
human tumor xenografts in immunodeficient (SCID) mice
[28]. Other natural inhibitors include herbimycin A,
quercetin and herbstatin. Notably, quercetin has been the
first tyrosine kinase inhibitor used in a phase I clinical trial
on cancer patients [29].
More interesting molecules belong to three classes of
compounds: 4-anilinoquinazolines, 4-[aryl-alkyl-amino]
pyridopyrimidines, 4-phenylaminopyrrolo-pyrimidines. On
these synthetic drugs the pharmaceutical industry
concentrated many efforts to prepare potent anticancer drugs
for clinical development. These agents have variable
selectivity for EGF receptor family tyrosine kinases and
different physico-chemical characteristics. Among the several
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EGF receptor tyrosine kinase inhibitors, CI-1033, OSI-774,
PKI-166 and ZD1839 have been used in clinical trials at
different phases.
ZD1839 [“Iressa”, chemical name: 4-(3-chloro-4-
fluoroanilino)-7-metoxy-6-(3-morpholinopropoxy) quinazo-
line] is a low-molecular-weight synthetic compound that can
be administered per os, either alone or in combination with
cytotoxic agents, with an excellent tolerability, diarrhea and
acneiform skin rash being the most frequently adverse
events. Anticancer activity has been demonstrated for
colorectal, ovarian, non-small cell lung, renal, head and neck
and some prostate tumors [30, 31]. The antiproliferative
effects of ZD1839 in combination with cytotoxic drugs
(e.g., cisplatin, carboplatin, paclitaxel, doxorubicin,
etoposide, topotecan etc.) have been evaluated on different
human cancer cell lines, co-administration of ZD1839
markedly enhancing anti-tumor activity of all cytotoxic
drugs tested [32-34]. ZD1839 is able to inhibit in vitro the
tyrosine kinase activity of EGF receptor with an IC50 of 23
nM, whereas more than hundredfold higher concentrations
are required to inhibit other similar kinases (HER2) or those
of other families (KDR, Flt-1) [35]. It delays cell cycle
progression by disrupting the regulation of cyclin-dependent
kinase-2 (CDK2) in some human tumor cultured cells [35].
Interestingly, other specific quinazoline derivatives (AG-
1478 and AG-1517) not only compete with ATP, but in
addition induce the sequestration of the receptor into
inactive, unphosphorylated dimers in A431 carcinoma cells.
Moreover, these drugs cause ligand trapping into these
inactive complexes, reducing the availability of active
growth factor molecules [36, 37].
OSI-774 [chemical name:6,7-bis(2-metoxy-ethoxy)-
quinazolin-4-yl-(3-ethynylphenyl)amine] is a quinazoline
derivative, reversible ATP competitive inhibitor, that
provokes cell cycle arrest in G1. It has been demonstrated to
induce apoptosis in a colon cancer cell line [26]. It can be
administered orally on a daily schedule, with low toxicity
except for diarrhea and acneiform skin rash, as in the case of
ZD1839. It showed anticancer activity or long periods of
stable disease in patients with advanced solid tumors, such
as colorectal, breast, kidney, non-small cell lung and other
epidermoid malignancies [38]. OSI-774 is even more active
than ZD1839, its IC50 being 2 nM on inhibition of purified
EGFR kinase activity. It is now in phase II trial for the
treatment of advanced head and neck, non-small cell lung
and ovarian tumors.
CI-1033 is the water soluble analog of PD183805,
[chemical name: 4-(-3-(chloro-4-fluoro-phenylamino)-7-(3-
morpholin-4-yl-propoxy)-quinazolin-6-yl)-acrylamide dihyd-
rochloride]. It is an irreversible inhibitor of all members of
the EGF receptor family (pan-erbB inhibitor). Also for this
drug diarrhea and skin rash are the typical adverse effects
[39]. It has been demonstrated that CI-1033 inhibits Akt
activation induced by tyrosine kinases of the erbB family. In
combination with gemcitabine treatment, it induces a strong
pro-apoptotic effect, which is evoked by the tyrosine kinase
inhibitor alone in the presence of constitutive p38 MAPK
activation [40].
PKI-166 [chemical name: 4-(R)-phenethylamino-6-
(hydroxyl)phenyl-7H-pyrrolo[2,3-d]-pyrimidine] is a tyrosine
kinase inhibitor that revealed as a valid therapeutic tool for
the treatment of human pancreatic carcinoma, alone or in
combination with gemcitabine. It inhibits growth and
metastasis of pancreatic carcinoma xenografts in nude mice,
which are associated with a significant reduction in tumor
production of VEGF and IL-8. This reduction correlates with
decrease in microvessel density and with induction of
extensive apoptosis of tumor-associated endothelial cells
[41, 42].
Recently, a series of novel dual ErbB2/EGF receptor
tyrosine kinase inhibitors have been proposed as potential
therapeutic agents. These are quinazoline and
pyridopyrimidine derivatives. The dual inhibition capacity is
due to the 4-anilino substitutions of previously characterized
drugs. These agents were investigated by tumor xenografts
experiments (where they exerted a significant tumor growth
inhibition already at 10 mg/kg per os) and were well
tolerated by the animals even at higher doses. The most
potent of these new compounds was GW2974 [43].
TYROSINE KINASE INHIBITORS OF THE PDGF
FAMILY (PDGF RECEPTOR, C-KIT)
Tyrosine Kinase Inhibitors of PDGF Receptor
PDGF (Platelet-derived growth factor), originally
identified in whole blood serum and purified from platelets,
is a family of disulfide-bonded dimeric isoforms [44].
Traditionally, the PDGF isoforms consisted of homo- and
heterodimers of structurally similar A- and B-polypeptide
chains; two novel members of this family, namely PDGF-C
and PDGF-D, have been recently identified [45]. Many
different cell types are able to synthesize PDGF; synthesis is
often increased in response to external stimuli, i.e., hypoxia,
thrombin or stimulation with various growth factors and
cytokines [44, 45]. PDGF isoforms exert their biological
effects by binding to and activating two structurally related
tyrosine kinase receptor, namely the α- (PDGF-A, -B and
–C) and the β-receptor (PDGF-B and –D) [45].
Activation of PDGF receptors leads to stimulation of cell
growth, chemotaxis, changes in cell shape and motility.
PDGF and its receptors play a major role in embryonic
development, wound healing, regulation of vascular system.
Overexpression of PDGF has been linked to several
disorders, and especially, atherosclerosis and fibrotic
conditions [44]. The sis oncogene of simian sarcoma virus
(SSV) is related to the β-chain of PDGF [46, 47] and SSV
transformation involves autocrine stimulation by a PDGF-
like molecule [48, 49]. Many different human tumors
express elevated levels of PDGF and cognate receptors,
correlating with poor response to chemotherapy and shorter
survival times [50]. Thus, the finding that PDGF induces
transformation and malignancy in experimental systems
suggests a role for PDGF in the development of spontaneous
tumors in man [50, 51].
Therefore, experimental research was settled to design
synthetic agents able to block the activity of the complex
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between PDGF and its receptor. Among the different
available molecules, interest has been largely focused to
PDGF receptor inhibitors STI571, SU 101 and GFB-111
[50, 51].
The tyrosine kinase inhibitor STI571 (see below), also
known as imatinib mesylate, not only blocks Bcr-Abl and c-
Kit, but is also a potent inhibitor of the PDGF receptor
kinase and is currently being evaluated for treatment of
PDGF-responsive tumors such as prostate cancer [52].
SU101 (or leflunomide), originally described and
developed as an inhibitor of dihydroorotate dehydrogenase (a
key enzyme of the pyrimidine pathway), has been marketed
in 1998 as an anti-rheumatoid arthritis agent [53]. However,
SU101 was also shown to inhibit, at micromolar
concentrations, different tyrosine kinases [54, 55]. It was
demonstrated as an effective inhibitor of PDGF-mediated
signal transduction and tumor growth [56] and as an EGF
receptor inhibitor [57]. Leflunomide/SU101 yields an active
metabolite (SU0020 or A771726), that inhibits COX-2
activity in vitro [58]. SU101 was well tolerated in a Phase I
study in cancer patients, when administered as a 24-hour
continuous i.v. infusion at doses up to 443 mg/m2/week
[59]. At this dose, the plasmatic concentrations of its
metabolite were able to block PDGF- and EGF- receptor
signaling, as well as pyrimidine biosynthesis [59]. Mild
nausea, vomiting and fever (but no hemolysis and
hematopoietic toxicity) were observed in about 20% of all
courses given [59]. SU 101 has been reported to be in
advanced trials for multiple solid tumor types, although
some problems and uncertainties have arisen [51].
GFB-111 (Growth Factor Binder-111) is the most
representative of a novel series of protein surface binding
agents, composed of a central calix[4]arene scaffold to which
are attached four peptide loop domains [50, 60]. Several
peptide loop sequences have been synthesized to obtain
molecules with negative and positive charged regions as well
as hydrophobic regions, capable of binding to
complementary areas on the target growth factor [50, 60]. A
series of hydrophobic and positively charged aminoacids in
loops I and III of one monomer and loop II of the head-to
tail linked second monomer represent the critical residues for
PDGF binding to its receptor [50]. As far as VEGF is
concerned, its receptor binding regions are composed of
hydrophobic and negatively charged regions [61], whereas
EGF has a completely different structure to PDGF and
VEGF [62]. Therefore, given the variance of the receptor
binding domains of these three growth factors, this approach
is suitable to design molecules able to bind selectively to a
target growth factor. Indeed, the negative charged and
hydrophobic portions of GFB-111, by matching the positive
and hydrophobic surface of PDGF, are responsible for its
selectivity versus PDGF. GFB-111 binds to PDGF,
prevents the binding of PDGF to its receptor tyrosine
kinase, blocks PDGF-induced receptor autophosphorylation,
activation of Erk1 and Erk2 kinases and DNA synthesis
[60]. It is a potent and selective PDGF antagonist (IC50 =
250 nM), it inhibits also VEGF-induced Flk-1 tyrosine
phosphorylation (IC50 = 10 µM), whereas IC50 values vs
EGF, IGF-1 and FGF are above 100 µM [60]. GFB-111
(50-200 mg/kg/day) is demonstrated to inhibit tumor growth
(human glioblastoma and human lung adenocarcinoma) and
angiogenesis in nude mice, suggesting its possible value in
treating a wide spectrum of human cancers [60].
Tyrosine Kinase Inhibitors of SCF (Stem Cell Factor)-
Receptor (c-Kit)
The c-Kit receptor, a transmembrane 145-kDa protein, is
essential for the development of normal hematopoietic cells
and has been suggested to play a significant role in acute
myeloid leukemia [63]. Binding of Stem Cell Factor (SCF)
to the c-Kit receptor results in autophosphorylation on
tyrosine and activation of its kinase activity. In mice, natural
occurring mutations at Stl locus (which encodes SCF) or in
the c-Kit receptor result in macrocytic anemia, dramatic
decrease in mast cells, alterations in gametogenesis and
melanogenesis [64]. Although it is not expressed in mature
peripheral blood cells, c-Kit is normally expressed in
hemopoietic cells, melanocytes, germ cells as well as a
variety of solid tumors [65]. Co-expression of both c-Kit
and its ligand SCF has been reported in myeloid leukemia,
neuroblastoma, breast tumors, colon tumors, gynecological
tumors, testicular germ cell tumors and at least 70% of
SCLC (small cell lung cancer) cell lines and tumor
specimens [66].
SU 5416 and SU6668, besides inhibiting Flk-1/KDR
(see below), dose-dependently inhibit c-Kit kinase activity in
MO7E cells [67]. Both compounds inhibit tyrosine
phosphorylation of c-Kit as well as SCF-induced
proliferation, IC50 values being 0.1 and 0.29 µM for SU
5416 and SU 6668, respectively, and also induce apoptosis
[67]. Their therapeutic effect could therefore be dual:
inhibition of c-Kit may reduce blast proliferation and overall
cell number, while inhibition of Flk-1/KDR-mediated
signaling in endothelial cells, may reduce either the
proliferation of endothelial cells than the production of
growth factor, such as CSF, stimulating the proliferation of
blast cells [67].
Similar results were obtained in leukaemic blasts from c-
Kit positive patients [67]. Moreover, SU 5416 treatment has
not been associated with myelodepression or anemia [68]
and indolinone derivatives related to these SU compounds
killed neoplastic mast cells expressing constitutively
activated forms of c-Kit [69].
Other tyrosine kinase inhibitors that block SCF-
dependent proliferation have been described. AG1295 and
AG1296, quinazoline derivatives competing for ATP
binding, inhibit SCF-mediated Kit activation and SCF-
mediated proliferation of SCLC cells [70]. AG1295 also
inhibit the tyrosine kinase activity of PDGF and FLT3,
receptors closely related to c-Kit, and is selective cytotoxic
to acute myeloid leukemia blasts that present internal
tandem duplication mutations in the juxtamembrane region
of the cytoplasmic domain of FLT3 [71].
STI571 (see also below), a 2-phenylaminopyrimidine
derivative originally established as an ATP competitive
inhibitor of Bcr-Abl [72], is able to inhibit SCF-stimulated
cell growth, c-Kit autophosphorylation, activation of
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mitogen-activated protein (MAP) kinase and activation of
Akt with an IC50 of 100 nM [73, 74].
Thus, inhibition of c-Kit as well as PDGF receptor could
account for clinical efficacy of STI571 in chronic myeloid
leukemia, as well as for its toxic side-effects (neutropenia),
as c-Kit and PDGF receptor are both believed to play
important roles in maintaining bone marrow stroma-
progenitor cells interactions [75, 76].
Substituted indolinones have been identified as suitable
chemical structures to design tyrosine kinase inhibitors. By
modifying the substituents on the pyrrole and oxindole rings
it is possible to modulate the potency of selectivity of these
compounds for inhibition of certain kinases [77, 78]. These
compounds have been demonstrated to be particularly
effective in inhibiting the kinases of the PDGF receptor
family that includes VEGF receptor and Kit. Among these
compounds, SU 6597 seems to be more selective for the c-
Kit kinase [66], offering a new approach to inhibit c-Kit-
mediated proliferation of SCLC, gastrointestinal stromal
tumors, seminomas and leukemias.
Tyrosine Kinase Inhibitors of VEGF Receptor Family
VEGF (Vascular Endothelial Growth Factor) is a family
of at least six 32 to 43 kDa proteins: VEGF-A (or VEGF),
PIGF, VEGF-B, VEGF-C, VEGF-D and VEGF-E (orph
virus VEGF) [79]. VEGF is expressed in different tissues
(e.g., brain, liver, spleen, and kidney) and cells, having a
more restricted expression on endothelial cells than on other
types [79]. VEGF regulates vascular permeability in vivo and
has a pronounced angiogenic effect in vitro. Different growth
factors and cytokines, including PDGF, EGF, TNF-α, TGF-
β and IL-1β induce VEGF mRNA transcription; therefore,
VEGF can also function as a mediator for indirect-acting
angiogenic factors [80]. VEGF levels are regulated by tissue
oxygen tension, hypoxia inducing VEGF expression and
normoxia down-regulating VEGF production [81, 82].
Two high-affinity binding sites for VEGF, namely
VEGFR-1 (or Flt-1) and VEGFR-2 (KDR, human
homologue or Flk-1, murine homologue: fetal liver kinase-
1), have been identified on endothelial cells, receptor gene
expression being regulated by hypoxia [83].
These two tyrosine kinase receptors seem to mediate
different biological VEGF activities. While VEGFR-2
(KDR) is known to induce endothelial cell proliferation,
migration, differentiation, tube formation, increase in
permeability and maintenance of vascular integrity [84],
VEGFR-1 (Flt-1)  has been implicated in
monocyte/macrophage migration and is thought to be the
main receptor to which VEGF binds in hematopoietic
progenitor cells [85, 86]. On the contrary, VEGFR-3 (Flt-4)
is not a receptor for VEGF, but binds VEGF-C and VEGF-
D [79].
Different observations strongly support the major role
played by VEGF and its receptors in tumor angiogenesis,
tumor growth and metastasis [87, 88]. Elevated VEGF
levels are often measured in sera from cancer patients, VEGF
production being closely associated with poor prognosis
[89]. Even more important is the observation that disruption
of VEGF signaling through Flk-1/KDR potently inhibits
tumor growth in animal models: a dominant-negative Flk-1
mutant not only blocked endothelial cell proliferation, but
also inhibited the growth of eight out nine tumor cell lines
implanted subcutaneously into athymic mice and markedly
reduced vessel density in tumors [90, 91]. On these bases,
neutralizing antibodies to VEGF and small molecules able
to inhibit Flt-1/KDR tyrosine kinase activity have been
developed as potential anti-cancer drugs.
The first receptor antagonist to enter clinical trial was
SU5416 [chemical name: 3-[(2,4-dimethylpyrrol-5-
yl)methylidenyl-indolin-2-one]. It is a potent, ATP-
competitive inhibitor, which selectively blocks VEGF-
induced phosphorylation of Flk-1, displays potent antitumor
activity in animals and induces endothelial cell apoptosis as
well as tumor cell apoptosis [92, 93]. It is regarded as a
selective inhibitor (Ki value= 0.16 µM) of Flk-1/KDR
kinase activity [94], is 20-fold less potent in inhibiting
PDGF receptor phosphorylation in cells, is a weak inhibitor
of FGF receptor (Ki = 10.5 µM), does not inhibit EGF
receptor and has IC50 values around 10 µM or more against
IGF-1 receptor, Met, Src, Abl and Lck [68, 92, 94]. SU5416
potently blocks the KDR-mediated VEGF-dependent (but
not FGF-dependent) proliferation of HUVECs (IC50 = 40
nM) and inhibits angiogenesis in vivo [68, 92].
Consistently, it inhibits the growth of different tumor
xenograft models, although it does not inhibit the
proliferation of the same tumor cells in culture [68, 92].
SU5416 has a short (about 30 min) plasma half-life in
mice and rats [94] and has usually been administered daily;
however, its efficacy was demonstrated also when given
twice weekly [68]. The fact that SU5416 has a long-lasting
biological effect despite its short plasma half-life and its
competitive inhibition of Flk-1 tyrosine kinase activity,
suggested this agent to be retained in the cell. Indeed, by
using radiolabeled compound, it was demonstrated that
human endothelial cells in vitro are capable of accumulating
SU5416 so that inhibitory intracellular concentrations of this
agent are maintained long after its removal from the medium
[68]. This long-term inhibitory activity is probably due to
the hydrophobic nature of SU5416, since less hydrophobic
compounds (e.g., SU6668) do not show long-lasting
activity or accumulation into the cells [68].
Another key element for this Flk-1 selective inhibitor is
its ability to enhance, in animal models, radiation effect,
with complete destruction of tumor blood vessels within 24
hours of treatment, and to reverse tumor resistance to
radiotherapy [95]. Furthermore, SU5416, in a dose-
dependent manner, causes apoptosis in a c-Kit-positive
human myeloid leukemia cell line (e.g., MO7E cells) and it
has been successfully used to induce a stable remission in a
65-year-old woman with refractory acute myeloid leukemia
[96].
As a matter of fact, SU5416 is under clinical trials for
Kaposi’s sarcoma, lung cancer, colon and metastatic colo-
rectal cancer, breast cancer and prostate cancer [51, 97, 98].
Phase I studies were performed on 69 advanced cancer
patients treated i.v. twice weekly with SU 5416 (4.4 – 190
mg/m2/day): at the highest level, a dose limiting toxicity
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(projectile vomiting, mainly) was observed [99]. Despite its
short plasma half-life, a twice-weekly i.v. administration of
SU5416 resulted in an increased time to disease progression
in patients with advanced malignancies and Kaposi’s
sarcoma [100, 101]. SU5416 has further advanced into Phase
II/III trials at an initial recommended dose of 145 mg/m2,
within the range of human maximally tolerated dose, and
large studies have been planned to assess the efficacy of
SU5416 (alone or in combination with standard anticancer
therapy) in both colorectal cancer and NSCLC [51].
As tumor cells are known to produce different cytokines
and growth factors and switch from the production of a
given factor to another, selective inhibition of a single
growth factor might allow only a partial control of tumor
growth. This idea led to the development of SU6668, a less
selective inhibitor with a more favorable pharmaceutical
profile [102]. SU6668 inhibits VEGF, FGF-2 and PDGF
tyrosine kinase receptors: it has a significantly lower Ki
value for PDGF receptor (8 nM) relative to VEGF (2.1 µM)
and FGF (1.2 µM) receptors [93, 102].
As SU5416, SU6668 has been found to be potent and
effective in different cancer models with the advantage to be
dosed orally. When administered per os (100-1600
mg/m2/day) to 16 patients with advanced malignancies, no
dose-limiting toxicity was observed, although two patients
at the highest dose presented liver abnormalities [103]. Side-
effects included nausea, headache, and fatigue [103].
Other inhibitors targeted to VEGFR include compounds
from Astra Zeneca (ZD4190, ZD6474) and Novartis (PTK
787).
ZD4190 is a quinazoline-based compound which inhibits
KDR (IC50 = 29 nM) and Flt-1 (IC50 = 708 nM) and is
much less potent in inhibiting FGF receptor (about 200-fold
as compared to KDR); it is also 30-fold more potent in
inhibiting VEGF-induced endothelial cell proliferation (IC50
= 50 nM) as compared to the FGF-induced one (IC50 =
1530 nM) [104]. ZD6474 shows very promising preclinical
results, as it induces significant regressions in PC-3 tumors
of different size, being more effective in the largest tumors
[105]. When used intermittently (one month withdrawal in
treatment schedule), tumor re-growth could be stopped and
regression was again observed in these tumors upon re-
treatment [105].
PTK 787 has an anilinophthalazine structure related to
but distinct from the quinazoline derivatives described above
[106]; it is a potent inhibitor of VEGF receptors (IC50 values
are 37 and 77 nM, for KDR and Flt-1), inhibits, at
submicromolar concentrations, PDGF receptor and c-Kit, but
does not affect v-Abl, EGF receptor and FGF receptor [107].
PTK 787 also inhibits VEGF-induced KDR
autophosphorylation, proliferation and enhances endothelial
cell apoptosis [107]. This compound demonstrates an
elevated anti-tumor and antiangiogenic activity in in vivo
animal models as well as a good pharmacokinetic profile (it
is active per os and reaches optimal plasmatic
concentrations). Moreover, it seems to be more active in
inhibiting tumor angiogenesis than in blocking normal
angiogenesis, such as that of wound healing [107].
Tyrosine Kinase Inhibitors of BCR-ABL
The product of chromosome rearrangement Bcr-Abl is
not a receptor tyrosine kinase, because the catalytic portion
of this molecule is a kinase of the cytosolic type. However,
this oncoprotein shares the same localization with membrane
receptors and has a constitutively activated kinase and
therefore is examined here.
STI571 (Signal Transduction Inhibitor-571, formerly
CGP57148B; imatinib mesylate; chemical structure: 4-[(4-
methyl-1- piperazinyl) methyl] - N-[4-methyl-3-[ [4-(3-
pyridinyl]- 2- pyrimidyl] amino] phenyl] benzamide
methanesulfonate) is the first synthetic tyrosine kinase
inhibitor to be approved (GlivecR, GleevecR) for the therapy
of Chronic Myeloid Leukemia (CML) and for
gastrointestinal stromal tumors (May 2001 and February
2002, respectively) [108].
The main feature of CML is the presence of a specific
chromosomal translocation [109] between the long arms of
chromosomes 9 and 22, resulting in a shortened
chromosome 22, commonly known as the Philadelphia (Ph)
chromosome [110]. The molecular consequence of this
translocation event is the fusion of the c-Abl oncogene (the
human equivalent of v-Abl, originally isolated from the
genome of the Abelson murine leukemia virus [111]) from
chromosome 9 to sequences of chromosome 22, the
breakpoint cluster region (BCR), to give the chimeric BCR-
ABL gene [112]. This gene encodes a fusion protein of
variable size: p185 and p210 are the most frequent proteins,
the latter being present in about 95% of patients with CML
[113]. These fusion proteins have constitutive tyrosine
kinase activity, which causes activation of intracellular
pathways leading to profound alterations in proliferation,
adhesion and survival of CML cells [114]. In vitro studies
and studies in animal models clearly established that Bcr-
Abl oncoprotein per se is sufficient to cause CML, and
mutational analysis demonstrated that the tyrosine kinase
activity of the protein is essential for its transforming ability
[115 – 117].
Therefore, experimental researches were targeted to find a
small molecule that could inhibit the Bcr-Abl tyrosine
kinase activity and so obtain an effective and selective
treatment for CML.
A phenylaminopyrimidine derivative, then called CGP
57148B (and later STI571), was able to occupy the kinase
pocket in the Bcr-Abl protein and to block the access to
ATP, so preventing the phosphorylation of substrate
molecules [118 – 120]. Preclinical studies demonstrated that
this molecule was very effective in blocking the tyrosine
kinase activity of Bcr-Abl, the stem-cell factor receptor (c-
Kit) and the PDGF receptor, but had little effect on other
tyrosine kinases [118, 120]. Moreover, STI571 blocked the
growth and apoptosis in hematopoietic cells that express
Bcr-Abl, but did not affect normal cells [118].
In a recently reported phase I clinical trial, STI571 was
given orally (from 25 to 1000 mg/day) to 83 patients with
CML in the chronic phase in whom interferon-α treatment
had failed [121]. The drug was well tolerated (the maximal
tolerated dose could not be identified), the most common
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adverse effects being nausea, myalgia, edema and diarrhea.
Complete hematological responses occurred in 53 out 54
patients treated with 300 mg or more STI571, within one
month from the beginning of therapy; 54% of patients
treated with at least 300 mg/day had cytogenetic responses
occurring relatively rapidly [121].
A second dose-escalating study evaluated STI571
antitumor activity in 38 patients with myeloid blast crisis
and 20 patients with acute lymphoblastic leukemia or
lymphoid blast crisis [122]. They were treated orally with
doses ranging from 300 to 1000 mg/day. Side effects were
similar to those reported in the first study; responses
occurred in 55% of patients with myeloid blast crisis and
70% of patients with the two other conditions [122].
Unfortunately, almost all patients relapsed after a median
time of 58 days, indicating that the responses in these
clinical conditions are short lasting, at variance with what
observed in chronic phase. In 11 patients with advanced
CML who underwent disease progression after an initial
response to STI571, reactivation of BCR-ABL signaling
occurred always despite continued drug administration [123].
The mechanism of resistance was a consequence of
mutation (in 6 patients a single aminoacid substitution in a
threonine residue of the Abl kinase domain, which is known
to form a critical hydrogen bond of the drug, was identified)
or amplification (3 patients) of the target oncogene Bcr-Abl;
one patient had both abnormalities [123]. As previously
mentioned, STI571 inhibits also the tyrosine kinase activity
of c-Kit (see also above), whose role in gastrointestinal
stromal tumor is largely envisaged [124].
A recent case report showed an impressive tumor
regression with STI571 400 mg/day in a patient with
metastatic gastrointestinal stromal tumor, who had
previously demonstrated inconsistent results to
chemotherapy with different agents [125]. As mentioned
above, on February 2002 the US Federal and Drug
Administration approved STI571 for the treatment of
gastrointestinal stromal cancers [108]; this suggests the
usefulness of STI571 for a therapeutic approach of other
malignancies, too.
More potent and highly selective RTK inhibitors, as well
as phosphatase inhibitors/activators, will be developed in the
next few years and we can anticipate that the drugs
interfering with phosphorylation-mediated signaling
pathways will become a major class of drugs for anticancer
therapy.
POSSIBLE NEW TARGETS FOR ANTICANCER
THERAPY: THE MET RECEPTOR FAMILY
In an attempt to identify new possible targets for
anticancer therapy, different preclinical observations point to
the Met receptor family as a likely candidate.
The Met Receptor Family
The Met receptor subfamily belongs to the RTK family
of cell surface proteins and is composed by three members:
Met, the HGF/SF (Hepatocyte Growth Factor/Scatter Factor)
receptor, Ron/Stk, the Macrophage Stimulating Protein
(MSP) receptor [126, 127], and avian Sea, the chicken-MSP
receptor [128].
The Met receptor family has some peculiar features. Its
heterodimeric structure consists of a short extracellular α-
chain disulphide-linked to a longer transmembrane β–chain.
These receptors are expressed as precursor single-chain
molecule, proteolytically processed to generate the α/β-
heterodimer in the post-Golgi compartment by action of a
furin-like convertase. Following ligand stimulation, two
adjacent tyrosine residues in the activation loop, known as
major phosphorylation site, become phosphorylated,
resulting in an auto-catalytic activation of the receptor itself.
Conversely, the biological activity of the receptors of the
Met subfamily depends on a sequence of the carboxy-
terminal tail containing two phosphotyrosine residues,
which act as multifunctional docking sites for SH2-
containing effectors, activating an array of transduction
pathways [129]. Moreover, the extracellular region of the β–
chain of Met family shares regions of homology with
semaphorins and plexins, including Sema domain and the
MRS (cysteine-rich Met-related sequence [130]). The RTK
family of Met promotes a wide range of biological
responses, ranging from cell growth and proliferation to
differentiation, survival, migration and invasion.
Met Structure and Signal Transduction
The Met ligand is Hepatocyte growth factor (HGF), also
known as scatter factor (SF). Both molecules were
independently identified by their abilities to promote the
prol i fera t ion  of  pr imary hepatocytes  and
dissociation/motility of epithelial cells, respectively [131,
132]. Molecular cloning of the cDNAs encoding both factors
revealed their identity [133].
HGF/SF is the prototype of a family that includes the
macrophage stimulating protein (MSP), ligand of Ron/Stk
and Sea RTKs. HGF/SF is a large heterodimeric protein,
which shares sequence similarities with the serine-proteases
of the coagulation cascade. It is secreted as single chain
glycoprotein precursor and activated in the extracellular
environment by specific proteases to form a α–β disulphide-
linked heterodimer. The α subunit has a molecular weight of
62 kDa and contains an amino-terminal hairpin loop and
four typical kringle domains, similar to those found in the
coagulation factors, which probably act as protein-protein
interaction motifs. The α  chain contains also the high-
affinity binding site for Met and the low-affinity binding
site for the heparan sulphate proteoglycans, whose effect
seems to be the sequestration of HGF in the proximity of
the producing cells, ensuring a local mechanism of action.
The 32/34 kDa β subunit is closely related to the catalytic
domain of serine-proteases, but the serine residue involved
in the catalysis is replaced by a tyrosine amino acid,
abolishing its enzymatic activity.
Met tyrosine kinase receptor is a 190-kDa transmembrane
protein, composed of a α subunit of 50 kDa disulphide-
linked to a β  subunit of 145 kDa, which contains the
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catalytic activity [134]. Upon HGF binding and subsequent
dimerization of Met, the receptor molecules undergo to in
trans auto-phosphorylation in the cytoplasmic portion of the
protein. Phosphorylation of tyrosine residues in the kinase
domain (Y1234 and Y1235), conserved among other RTKs,
determines the activation of the enzymatic activity of the
Met receptor. In particular, Y1235 constitutes the major
phosphorylation site. Substitution of both residues with
phenylalanine does not affect the receptor tyrosine kinase
activity, but abolishes completely its biological effects
[135].
The activation of the receptor leads to
autophosphorylation of tyrosine residues of the intracellular
portion, embedded in specific amino acid sequence, which
acts as docking site for SH2 domain containing proteins.
This sequence Y1349VHVNATY1356VNV is responsible for
the binding of various proteins, which include Grb2/Sos
complex, pp60c-Src, PI3-kinase, PLC-γ, Shc, Shp-2 and
STAT3 [129, 136-139] and is therefore referred as Met
multifunctional docking site. It was found that Grb2 is only
recruited by Y1356, whereas the other proteins bind to both
the tyrosine residues. The multifunctional docking site of
Met is also able to interact with Gab1 (Grb2-associated
binding protein), via a novel phosphotyrosine-binding
domain (MBD or Met-binding domain) [140].
Conversely, in other cases Grb2 can serve to attenuate
HGF receptor signaling, by enhancing receptor
downregulation. Upon stimulation with HGF, the
intracellular portion of the β–chain of Met is rapidly poly-
ubiquitinated and degraded in a proteasome-dependent
manner [141]. Met ubiquitination has been shown to be
promoted by c-Cbl, an adapter protein involved in RTK
downregulation through its E3 ligase activity. Cbl is able to
interact to HGF receptor directly, through a juxtamembrane
tyrosine residue (Y1003), or indirectly via Grb2, involving
the residue Y1356 of the C-terminal tail of Met [142]. The
same residue Y1003 has been previously indicated to
negatively regulate receptor activity through the binding of
the protein tyrosine phosphatase PTP-S [143]. Another
amino acid residue located in the juxtamembrane domain of
Met and critical for negative regulation of the receptor is
Ser985, which is a phosphorylation site for the protein
kinase C [144].
The negative function of juxtamembrane domain is also
demonstrated by experiments involving the constitutively
activated version of the HGF receptor, Tpr-Met oncoprotein.
In Tpr-Met, the regulatory juxtamembrane region is absent
and replaced by spontaneously dimerising leucine zipper
motif [145]. The transforming activity of Tpr-Met is
postulated to reside both in the constitutive active form of
the protein, due to dimerization motifs in Tpr sequence, and
in the absence of residues S985 and Y1003, responsible for
Met negative regulation.
Met and Cancer
In several epithelial tumors, including ovarian, pancreas,
colorectal and thyroid carcinomas, HGF receptor is
constitutively overexpressed and phosphorylated [146– 150].
Notably, protein overexpression was found to be associated
with amplification of Met  gene in only a few primary
carcinomas, but in a significant proportion of derived
metastasis, suggesting a crucial role for the invasive
properties of HGF receptor in promoting the metastatic
spread of neoplastic cells. Increased expression and/or
activity of the Met receptor have been associated with tumor
development and possibly tumor metastasis [151, 152].
A direct genetic connection between Met activation and
human cancer has been established by the identification of
germline and somatic mutations in patients affected by
papillary renal carcinoma [153]. All mutations were
missense and located within the tyrosine kinase domain of
the receptor, in a region termed activation loop. One
possibility is that mutations affecting these residues might
result in the displacement of the activation loop, increasing
catalysis. Interestingly, three of the mutations (D1228N,
D1228H and M1250T) are located in codons that are
homologous to those mutated in the receptor tyrosine
kinases c-Kit and Ret, causing mastocytosis with associated
hematological disorders, and Multiple Endocrine Neoplasia
type 2B, respectively.
In Ret receptor M918T mutation modifies a number of
receptor properties, including substrate specificity, ligand-
dependent activation, variation in the phosphorylation sites
and the interaction of signal transducers [154]. It is possible
that the homologous mutation M1250T will exert similar
effects in Met. In the Kit model, mutations of D814,
homologous to Met D1228, causes ligand independent
activation of the receptor together with alteration of the
substrate specificity [155].
Recently, it has been reported constitutive activation of
the Met receptor in cells derived from patients of Malignant
Mesothelioma (MM), an aggressive and invasive cancer,
associated to previous exposure to asbestos fibers. Infection
of human mesothelial cells by SV40 leads to a Tag-induced
HGF autocrine circuit, mediated by Retinoblastoma protein
interaction and inducing cell cycle progression into S-phase.
This suggests a model of viral-related carcinogenesis,
involving a RTK activation [156].
Recently, it has been reported a signaling adapter
function for α6β4 integrin in the control of HGF-dependent
invasive growth. Met selectively associates with α6β4 and
following Met activation, the integrin becomes tyrosine
phosphorylated and combines with Shc and PI3K,
generating an additional signaling platform that potentiates
HGF-triggered activation of Ras- and PI3K-dependent
pathways. These data indicate a role for α6β4 in cancer
invasion as a functional signal amplifier rather than an
adhesive device [157].
Downregulation of RTKs
As stated above, for many aspects of cell behavior, it is
important to start cellular signaling pathways as well as
switching them off again and failures in the deactivation
mechanisms often lead to cancer. Also RTKs must be
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inactivated, so that signaling evoked by growth factors can
be arrested. One of the inactivation mechanisms consists in
rapid clearance of the receptor from the surface, through
receptor-mediated endocytosis and degradation of ligand-
receptor complexes in the lysosome. During this process the
Cbl adaptor protein, that binds to specific docking sites on
activated RTKs via its SH2/PTB domain, is critical for the
appropriate sorting of the receptors. Cbl recruits the
enzymatic machinery responsible for ubiquitination of the
receptor, a process that accelerates its endocytosis and
delivery to lysosomes for degradation. [158].
It has been established that the degradation of EGF
receptor, Neu/HER2 and Met (HGF receptor) are mediated
by the ubiquitin-proteasome pathway [159 -161].
Recently, two synchronized reports demonstrate that a
complex made of Cbl, the adaptor CIN85 and the enzyme
endophilin, is recruited to tyrosine phosphorylated EGF
receptor and HGF receptors, accelerating the termination of
the biological activities of the two receptors [162, 163].
These results indicate for c-Cbl and associated proteins a
key role in sustaining an efficient downregulation of
activated RTKs. They also suggest that, as a general
mechanism, tethering oncogenic growth factor receptors to
the endocytic degradation pathway may be an applicable
approach for the suppression of transforming signaling
pathways and offer novel potential targets for the treatment
of malignancies.
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